Parity as an independent prognostic factor in malignant mixed mesodermal tumors of the endometrium

被引:13
作者
Marth, C
Windbichler, G
Petru, E
Dirschlmayer, W
Obermair, A
Czerwenka, K
MullerHolzner, E
Dapunt, O
机构
[1] UNIV INNSBRUCK HOSP,DEPT OBSTET & GYNECOL,INNSBRUCK,AUSTRIA
[2] UNIV HOSP,DEPT OBSTET & GYNECOL,GRAZ,AUSTRIA
[3] UNIV HOSP,DEPT OBSTET & GYNECOL,VIENNA,AUSTRIA
[4] HOSP BARMHERZIGEN SCHWESTERN,LINZ,AUSTRIA
关键词
MULLERIAN TUMORS; UTERUS;
D O I
10.1006/gyno.1996.4538
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Malignant mixed mesodermal tumors (MMMT) are the most malignant neoplasms known to occur in the uterus. The most important prognostic factors are the extent of tumor at diagnosis, depth of myometrial invasion, and, as regarded by some authors, the sarcomatous component, We report on a retrospective analysis in 83 patients with MMMT. By univariate analysis survival was dependent on stage, depth of myometrial invasion, kind of therapy, age at menopause, and parity. However, the sarcomatous component did not significantly influence survival. Using the multivariate Cox regression analysis stage and parity or depth of myometrial invasion and parity were found to independently predict prognosis. Despite an interval of more than 20 years from the last childbirth to tumor appearance a beneficial influence of parity on the prognosis of MMMT was identified. This is unique in oncology. Especially patients with more than three children formed a subgroup of long-term survivors. It is interesting to note that parity was found by means of a Cox regression analysis to be statistically independent, and no correlation with other classical prognostic factors was detected. (C) 1997 Academic Press
引用
收藏
页码:121 / 125
页数:5
相关论文
共 28 条
  • [22] Staging MRI of uterine malignant mixed Mullerian tumors versus endometrial carcinomas with emphasis on dynamic enhancement characteristics
    Garza, Alheli
    Elsherif, Sherif B.
    Faria, Silvana C.
    Sagebiel, Tara
    Sun, Jia
    Ma, Jingfei
    Bhosale, Priya R.
    ABDOMINAL RADIOLOGY, 2020, 45 (04) : 1141 - 1154
  • [23] Comparative Analysis of P16 and P53 Expression in Uterine Malignant Mixed Mullerian Tumors
    Buza, Natalia
    Tavassoli, Fattaneh A.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2009, 28 (06) : 514 - 521
  • [24] Staging MRI of uterine malignant mixed Müllerian tumors versus endometrial carcinomas with emphasis on dynamic enhancement characteristics
    Alheli Garza
    Sherif B. Elsherif
    Silvana C. Faria
    Tara Sagebiel
    Jia Sun
    Jingfei Ma
    Priya R. Bhosale
    Abdominal Radiology, 2020, 45 : 1141 - 1154
  • [25] Insulin-like growth factor II messenger RNA-binding protein-3 is an independent prognostic factor in uterine leiomyosarcoma
    Yasutake, Nobuko
    Ohishi, Yoshihiro
    Taguchi, Kenichi
    Hiraki, Yuka
    Oya, Masafumi
    Oshiro, Yumi
    Mine, Mari
    Iwasaki, Takeshi
    Yamamoto, Hidetaka
    Kohashi, Kenichi
    Sonoda, Kenzo
    Kato, Kiyoko
    Oda, Yoshinao
    HISTOPATHOLOGY, 2018, 72 (05) : 739 - 748
  • [26] P53 GENE MUTATION IN FEMALE GENITAL-TRACT CARCINOSARCOMAS (MALIGNANT MIXED MULLERIAN TUMORS) - A CLINICOPATHOLOGICAL STUDY OF 74 CASES
    COSTA, MJ
    VOGELSANG, J
    YOUNG, LJT
    MODERN PATHOLOGY, 1994, 7 (06) : 619 - 627
  • [27] Comparison of Survival Outcomes Between Patients With Malignant Mixed Mullerian Tumors and High-Grade Endometrioid, Clear Cell, and Papillary Serous Endometrial Cancers
    Felix, Ashley Sinclair
    Stone, Roslyn A.
    Bowser, Robert
    Chivukula, Mamatha
    Edwards, Robert P.
    Weissfeld, Joel L.
    Linkov, Faina
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2011, 21 (05) : 877 - 884
  • [28] USG guided fine needle aspiration cytology along with immunocytochemistry to diagnose primary malignant mixed mullerian tumors: A three-year study from a tertiary care center
    Agarwal, Radhika
    Singh, Meeta
    Goswami, Sneha
    Mandal, Shramana
    Verma, Devender
    Khurana, Nita
    Jain, Shyama
    Verma, Nidhi
    JOURNAL OF CYTOLOGY, 2022, 39 (01) : 9 - 13